touchINFECTIOUSDISEASES caught up with Craig Hoesley (Division of Infectious Diseases, University of Alabama School of Medicine, Birmingham, Alabama, US) to discuss the phase 1 trial investigating intrarectal dapivirine gel for HIV prevention.
Part 1 of our discussion can be viewed here.
His abstract entitled: ‘A randomized, double blind, placebo-controlled, phase 1 safety and pharmacokinetic study of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults (MTN-026)’ (OA16.05) was presented at the HIVR4P Virtual Conference 2021, 03 February 2021.
- What clinical evidence supports the development of an intrarectal formulation of dapivirine? (0:11)
- Could you tell us a little about the design and inclusion criteria of the MTN-026 study? (1:33)
- What were the findings of the study in terms of safety, pharmacokinetics and acceptability? (2:24)
- What will be the next steps in the clinical development of intrarectal dapivirine? (4:54)
Disclosures: Craig Hoesley has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of HIVR4P Virtual Conference 2021.
Share this Video
Related Videos In HIV
18th European AIDS Conference 2021: Welcome from Sanjay Bhagani
Dr Sanjay Bhagani invites you to join the 18th European AIDS Conference (EACS 2021). The conference will be organised in a hybrid format from October 27-30, 2021. The onsite Conference in London will take place, following a comprehensive COVID-19 health and safety concept, complemented by an engaging and interactive online platform that mirrors the scientific […]
Kelly Dooley, ECCMID 2021: Challenges in Developing New Treatments for Drug-resistant Tuberculosis
It was a pleasure to meet with Kelly Dooley (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the major challenges to developing new treatment regimens for drug-resistant tuberculosis. The session entitled: ‘New drugs and new regimens for treating drug-resistant tuberculosis’ was presented at the 31st European Congress of Clinical Microbiology & Infectious […]
David Lawrence, IAS 2021: Phase 3 AMBITION Trial Results
We had the pleasure to meet with David Lawrence (London School of Hygiene and Tropical Medicine, London, UK) to discuss the phase 3 AMBITION trial results investigating liposomal amphotericin for treatment of HIV-associated Cryptococcal Meningitis. The abstract entitled: ‘Single high-dose liposomal amphotericin based regimen for treatment of HIV-associated Cryptococcal Meningitis: results of the phase-3 Ambition-cm […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!